Research programme: mRNA based infectious disease vaccines - CureVac

Drug Profile

Research programme: mRNA based infectious disease vaccines - CureVac

Alternative Names: RNActive® infectious disease vaccines

Latest Information Update: 24 Jun 2017

Price : $50

At a glance

  • Originator CureVac
  • Class Influenza A vaccines; RNA vaccines; Rotavirus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 7 agonists; Toll-like receptor 8 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Influenza A virus infections; Respiratory syncytial virus infections
  • Research HIV infections; Rotavirus infections
  • No development reported Infections

Most Recent Events

  • 13 Jun 2017 CureVac has patent protection for its mRNA based vaccines in the US and Europe
  • 16 Jul 2016 No recent reports of development identified for research development in Infections(Prevention) in Germany (Intradermal, Injection)
  • 10 Sep 2015 CureVac and International AIDS Vaccine Initiative (IAVI) agree to co-develop AIDS vaccines for HIV infections (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top